A new case of t(4;12)(q12;p13) in a secondary acute myeloid leukemia with review of literature by Heaton, SM et al.






Case Report Section 
Paper co-edited with the European LeukemiaNet 
 
Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)   982 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
A new case of t(4;12)(q12;p13) in a secondary 
acute myeloid leukemia with review of literature 
Sarah M Heaton, Frederick Koppitch, Anwar N Mohamed 
Cytogenetics Laboratory, Pathology Department, Wayne State University School of Medicine, Detroit 
Medical Center, Detroit MI, USA (SMH, FK, ANM) 
Published in Atlas Database: March 2011 
Online updated version : http://AtlasGeneticsOncology.org/Reports/t0412HeatonID100051.html 
DOI: 10.4267/2042/46059 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Clinics 
Age and sex 
57 years old male patient. 
Previous history 
No preleukemia. Previous malignancy Hodgkin's 
Lymphoma, stage IVA at age 25 year, treated with 
ABVD for 12 months. Tumor mass in the upper 
cervical spine diagnosed at age 27 year, treated with 
laminectomy and five doses of radiation. No inborn 
condition of note. 
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged lymph 
nodes, no central nervous system involvement. 
Blood 
WBC : 0.8X 109/l 
HB : 9.7g/dl 
Platelets : 21.0X 109/l 
Blasts : 18% 
Bone marrow : Variably cellular with 20% 
myeloblasts and dysplastic changes in the erythroid and 




His bone marrow showed 60% blasts, and dysplastic 






Flow cytometry (FCM) revealed that the blasts were of 
myeloid lineage expressing CD13, CD33, CD34, 
CD117, HLA-DR, and CD56. 
Diagnosis 
Acute myeloid leukemia (AML) with dysplastic 
changes. 
Survival 
Date of diagnosis: 08-2007 
Treatment 
He was treated with Idarubicin+Ara-c (3+7) regimen. 
Because of 15% residual blasts in bone marrow, patient 
received additional 2+5 therapy, and then he underwent 
consolidation with Ara-C. Result of karyotype: 
46,XY[20]. On April 2008, the patient received a 
matched unrelated female donor stem cell transplant 
(SCT). 30 days post transplant; bone marrow revealed 
no morphological evidence of leukemia and the 
karyotype was 46,XX[20]. On June 2008; patient 
developed pancytopenia; WBC: 2.2 x 109/l; Hb: 11.6 
g/dl; platelets: 18.0 x 103/l. His bone marrow showed 
an increased dysplastic changes and <5% blasts, 
suggestive of possible early relapse. The karyotype 
became abnormal (see below). On June 2010; bone 
marrow was hypocellular with 20% blasts and 
dysplastic changes in the erythroid and myeloid 
lineages. FCM revealed myeloblasts expressing CD4, 
CD7, CD33, CD34, CD56, CD117 and HLA-DR. 
myeloperoxidase was negative. Non-specific esterase 
was positive in occasional blasts. Cytology: AML 
possibly of monocytic origin (AML-M5). 
Treatment related death : no 
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Figure 1. G-banded karyotype showing the balanced t(4;12)(q12;p13) translocation. 
 
Figure 2. FISH on abnormal metaphases; (A) Metaphase hybridized with LSI 4q12 tricolor DNA probe showed a translocation of 
PDGFRA (SA) to derivative chromosome 12 (arrow), with the dual fusion of spectrunOrange (SO) and spectrunGreen (SG) remained on 
derivative 4. (B) Metaphase hybridized with LSI ETV6/RUNX1 ES dual color probe revealed a split of ETV6 (SG) with the smaller signal 
being translcated to derivative 4 (arrows). (C) Metaphase hybridized with both LSI 4q12 and ETV6/RUNX1 probes showed PDGFRA 
(SA) translocted to derivative 12 adjacent to ETV6 locus (arrows). 
 
Phenotype at relapse: M5-AML 
Status: Alive. Last follow up: 06-2010. 
Survival: 24 months 
Karyotype 
Sample: Bone marrow 




46,XY,t(4;12)(q12;p13)[6]/46,XX[14] in June 2008 
(post transplant) 
Karyotype at Relapse 
46,XY,t(4;12)(q12;p13)[12]/ 
46,idem,del(7)(q22q36)[4]/ 47,idem,+19[2]/ 46,XX[2], 
consistent with the recurrence and clonal evolution of 
the leukemic clone. 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization (FISH) using LSI 
4q12 tricolor and LSI ETV6/RUNX1 ES dual color 
DNA probes were performed (Abbott Molecular. 
Downers Grove, IL) on the abnormal metaphase cells. 
 
Other molecular cytogenetics results 
Translocation of the PDGFRA gene in Toto, 
spectrunAqua (SA), to derivative 12 and colocalized 
with centromeric region of ETV6; Break within ETV6 
gene locus, sepctrunGreen (SG) and the telomeric 
region of ETV6 translocated to derivative 4 (Figure 2 
A-C). 
Comments 
Acute leukemia with t(4;12)(q11-q12;p13) is a rare, 
nonrandom event with an estimated incidence of 0.6% 
among adults according to Harada et al. (Harada et al., 
1997). This translocation is seen mostly in adult AML 
but less frequent in pediatric ALL (Hamaguchi et al.,
1999). A review of the literature revealed at least 
twenty-two additional cases with a t(4;12)(q11-
q12;p13); eighteen adults and four children. The male 
to female ratio is 1.5:1 (1.7:1 in adults and 1:1 in 
children). The majority of patients are adults, aged 18 
to 82 with the mean being 58.9 years old (Harada et al., 
1995; Harada et al., 1997; Ma et al., 1997; Cools et al., 
1999; Hamaguchi et al., 1999; Chaufaille et al., 2003; 
Manabe et al., 2010). Four children have been report d, 
aged 3-14 years old, of which three had ALL and the 
oldest had AML (Harada et al., 1997).  
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Among the 23 cases including our case with t(4;12) 
leukemia; 19 had AML; 3 ALL, and one unclassified 
leukemia. Common features to t(4;12) AML include 
dysplasia of three hematopoietic lineages (erythroid, 
myeloid and megakaryocytic), low or absent 
myeloperoxidase activity, basophilia and a pseudo-
lymphoid morphology. The surface markers of the 
blasts show positivity for CD7, CD13, CD33, CD34 
and HLA DR, suggesting that the leukemic cells have 
an immature myeloid stem cell origin (Harada et al.,
1995; Ma et al., 1997; Hamaguchi et al., 1999). Of the 
reported t(4;12) AML cases; seven were characterized 
as AML-M0 and four AML-M1. Previous reports 
suggest that less than 50% of cases achieve remission 
with intensive induction chemotherapy. Of the patients 
who do not achieve morphologic remission, none 
survived beyond six months (Hamaguchi et al., 1999; 
Chaufaille et al., 2003; Manabe et al., 2010).  
The breakpoint at 12p13 in t(4;12) AML is located 
within or near the ETV6 gene locus. The ETV6 gene 
has been implicated in both myeloid and lymphoid 
malignancies (Wlodarska et al., 1998). ETV6 belongs 
to the ETS family of transcription factors and has two 
important domains: HLH and an ETS DNA binding 
domain. Cools et al, found the t(4;12) caused the ETV6 
gene recombined to CHIC2 (formerly BLT) (Cools et 
al., 1999). A number of genes have been mapped to the 
band 4q12 including mac25, PDGFRA, AFP, and a 
beta-sarcoglycan gene (Hamaguchi et al., 1999).  
The case reported here shared some features to those
reported in the literature including positivity for CD7, 
CD33, CD34, CD117 and HLA-DR, lack of 
myeloperoxidase activity and dysplastic bone marrow. 
Unlike other reported cases, bone marrow basophilia 
and high platelets were not found. Clearly in our case, 
FISH showed a break within ETV6/12p13 gene, and 
colocalization of PDGFR1 gene to derivative 12 next to 
5’ ETV6 region. 
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